Literature DB >> 27652325

Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma.

Lawrence W Wu1, Gao Zhang1, Meenhard Herlyn1.   

Abstract

The acquisition of resistance to current mitogen activated protein kinase (MAPK) inhibitors in B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutant melanoma is almost inevitable. Our recent findings identify therapy-induced mitochondrial biogenesis (MitoBiogenesis) and aberrant tumor bioenergetics as therapeutic escape mechanisms and offer a rational combinatorial strategy to further improve the efficacy of MAPK inhibitors.

Entities:  

Keywords:  BRAF-mutant melanoma; mitochondrial biogenesis; targeted therapies

Year:  2016        PMID： 27652325      PMCID： PMC4972122          DOI： 10.1080/23723556.2016.1179381

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

3.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.

Authors:  Francisca Vazquez; Ji-Hong Lim; Helen Chim; Kavita Bhalla; Geoff Girnun; Kerry Pierce; Clary B Clish; Scott R Granter; Hans R Widlund; Bruce M Spiegelman; Pere Puigserver
Journal:  Cancer Cell       Date:  2013-02-14       Impact factor: 31.743

Review 4.  Melanoma in 2013: Melanoma--the run of success continues.

Authors:  Dirk Schadendorf; Axel Hauschild
Journal:  Nat Rev Clin Oncol       Date:  2014-01-14       Impact factor: 66.675

5.  Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.

Authors:  Gao Zhang; Dennie T Frederick; Lawrence Wu; Zhi Wei; Clemens Krepler; Satish Srinivasan; Young Chan Chae; Xiaowei Xu; Harry Choi; Elaida Dimwamwa; Omotayo Ope; Batool Shannan; Devraj Basu; Dongmei Zhang; Manti Guha; Min Xiao; Sergio Randell; Katrin Sproesser; Wei Xu; Jephrey Liu; Giorgos C Karakousis; Lynn M Schuchter; Tara C Gangadhar; Ravi K Amaravadi; Mengnan Gu; Caiyue Xu; Abheek Ghosh; Weiting Xu; Tian Tian; Jie Zhang; Shijie Zha; Qin Liu; Patricia Brafford; Ashani Weeraratna; Michael A Davies; Jennifer A Wargo; Narayan G Avadhani; Yiling Lu; Gordon B Mills; Dario C Altieri; Keith T Flaherty; Meenhard Herlyn
Journal:  J Clin Invest       Date:  2016-04-04       Impact factor: 14.808

6.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

7.  Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma.

Authors:  Y N Vashisht Gopal; Helen Rizos; Guo Chen; Wanleng Deng; Dennie T Frederick; Zachary A Cooper; Richard A Scolyer; Gulietta Pupo; Kakajan Komurov; Vasudha Sehgal; Jiexin Zhang; Lalit Patel; Cristiano G Pereira; Bradley M Broom; Gordon B Mills; Prahlad Ram; Paul D Smith; Jennifer A Wargo; Georgina V Long; Michael A Davies
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

8.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Authors:  Rizwan Haq; Jonathan Shoag; Pedro Andreu-Perez; Satoru Yokoyama; Hannah Edelman; Glenn C Rowe; Dennie T Frederick; Aeron D Hurley; Abhinav Nellore; Andrew L Kung; Jennifer A Wargo; Jun S Song; David E Fisher; Zolt Arany; Hans R Widlund
Journal:  Cancer Cell       Date:  2013-03-07       Impact factor: 31.743

9.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

Authors:  Hubing Shi; Willy Hugo; Xiangju Kong; Aayoung Hong; Richard C Koya; Gatien Moriceau; Thinle Chodon; Rongqing Guo; Douglas B Johnson; Kimberly B Dahlman; Mark C Kelley; Richard F Kefford; Bartosz Chmielowski; John A Glaspy; Jeffrey A Sosman; Nicolas van Baren; Georgina V Long; Antoni Ribas; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
  10 in total
  2 in total

Review 1.  Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment.

Authors:  Angelica Avagliano; Giuseppe Fiume; Alessandra Pelagalli; Gennaro Sanità; Maria Rosaria Ruocco; Stefania Montagnani; Alessandro Arcucci
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

2.  Acid Sphingomyelinase Downregulation Enhances Mitochondrial Fusion and Promotes Oxidative Metabolism in a Mouse Model of Melanoma.

Authors:  Marco Coazzoli; Alessandra Napoli; Paulina Roux-Biejat; Clara De Palma; Claudia Moscheni; Elisabetta Catalani; Silvia Zecchini; Vincenzo Conte; Matteo Giovarelli; Sonia Caccia; Patrizia Procacci; Davide Cervia; Emilio Clementi; Cristiana Perrotta
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.